The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the ...
SALT LAKE CITY, July 01, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home ...
Courtney Nugent struggled with anxiety so debilitating it led to multiple hospitalizations. It wasn’t until her provider personalized her mental health medication treatment with the help of the ...
SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet ...
Pharmacogenetic DNA testing via Genomind and GeneSight is available for appropriate patients. Psychiatry is a unique specialty that requires us to not only treat the brain, but also the mind. In my ...
SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet ...
SALT LAKE CITY, April 19, 2023 (GLOBE NEWSWIRE) -- From restricted or binge eating to excessive gambling to extreme social media use, 77% of Americans surveyed say they have used at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback